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Abstract
Background: Maternofetal transmission (MFT) of HIV-1 is relatively rare during the first trimester of pregnancy
despite the permissivity of placental cells for cell-to-cell HIV-1 infection. Invasive placental cells interact directly with
decidual cells of the uterine mucosa during the first months of pregnancy, but the role of the decidua in the
control of HIV-1 transmission is unknown.
Results: We found that decidual mononuclear cells naturally produce low levels of IL-10, IL-12, IL-15, TNF-a, IFN-a,
IFN-g and CXCL-12 (SDF-1), and large amounts of CCL-2 (MCP1), CCL-3 (MIP-1a), CCL-4 (MIP-1b), CCL-5 (Rantes),
CXCL-10 (IP-10), IL-6 and IL-8. CCL-3 and CCL-4 levels were significantly upregulated by in vitro infection with R5
HIV-1 but not X4. Decidual CD14+ antigen presenting cells were the main CCL-3 and CCL-4 producers among
decidual leukocytes. R5 and X4 HIV-1 infection was inhibited by decidual cell culture supernatants in vitro. Using
HIV-1 pseudotypes, we found that inhibition of the HIV-1 entry step was inhibited by decidual soluble factors.
Conclusion: Our findings show that decidual innate immunity (soluble factors) is involved in the control of HIV-1
infection at the maternofetal interface. The decidua could thus serve as a mucosal model for identifying correlates
of protection against HIV-1 infection.
Background
Cytokines are involved in cell activation, immune response
polarization and antiviral immunity, and play a key role in
innate immunity. In particular, cytokines and chemokines
can interfere with several steps of the Human Immunode-
ficiency Virus type 1 (HIV-1) replicative cycle. For
instance, type 1 interferon (IFN) can induce the transcrip-
tion of more than 100 genes, such as Mx1, OAS or
TRIM5a, thereby inhibiting reverse transcription [1] and
provirus integration [2]. Some chemokines inhibit HIV-1
entry by competitive binding to viral co-receptors [3,4]:
CCL-3, CCL-4 and CCL-5 interact with the CCR5 co-
receptor, thereby inhibiting the entry of R5 HIV-1, while
CXCL-12 binds to CXCR4 and thus inhibits X4 HIV-1
entry. In contrast, proinflammatory cytokines such as IL-6,
IL-12 and TNF-a stimulate HIV-1 replication by promot-
ing inflammation or proviral genome transcription [5-7].
Cytokines are also involved in physiological processes, for
example regulating blastocyst implantation during the first
trimester of pregnancy [8], as well as placental invasion [9]
and tolerance of the fetus [10].
Maternofetal transmission (MFT) of HIV-1 is rela-
tively rare, even in the absence of antiretroviral therapy.
R5 HIV-1 isolates are found in most cases of mother-to-
child transmission [11-16], and MFT usually occurs dur-
ing the last trimester [17] pointing to the existence of
effective natural control mechanisms particularly during
the first months of pregnancy. During the first trimester
of pregnancy the maternofetal interface is composed of
the placenta (the fetal part) and the maternal uterine
mucosa (decidua) [18]. Decidual tissue is defined by its
location and function: the decidua basalis is located at
the implantation site, in close contact with the placenta,
while the decidua parietalis lines the rest of the uterine
wall [19]. Blastocyst attachment to the decidua induces
placental cell differentiation. A contingent of placental
cells, known as extravillous trophoblast cells, invades the
decidua during the first trimester of pregnancy.
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tissue and are composed of natural killer cells (dNK),
antigen-presenting cells (dAPC), T lymphocytes (dT)
and small percentages of gδ T lymphocytes and NKT
cells [20]. These cells interact with one another and
with invading trophoblast cells. Trophoblast cells are
not permissive to cell-free HIV-1 infection [21,22] but
interaction between trophoblast cells and HIV-1-
infected cells allows infectious virions to cross the tro-
phoblastic barrier in an in vitro model [23]. We have
previously shown that first-trimester decidual tissue
contains HIV-1 target cells. CD14
+ dAPC are the main
targets of R5 HIV-1, while decidual T lymphocytes are
the main targets of X4 HIV-1 [24]. As MFT is rare dur-
ing the first trimester of pregnancy, cell-to-cell HIV-1
dissemination at the maternofetal interface appears to
be tightly controlled.
The aims of this study were to analyze decidual solu-
ble factors and their role in the regulation of HIV-1
infection at the maternofetal interface.
Results
Characterization of the main decidual mononuclear cell
populations
Fresh decidual samples were analyzed by immunohisto-
chemistry. As expected, tissue contained cytokeratin 7
+
placental cells and CD34
+ endothelial cells. A high num-
ber of immune decidual cells were also visualized in iso-
lated tissue (Figure 1); CD56
+ NK cells, CD14
+ antigen
presenting cells and CD3
+ T cells. After the digestion of
the tissue, mononuclear cells were analyzed by flow
cytometry. Immune cell populations present within the
decidua are shown on Figure 2 from one representative
experiment. As previously described [20,25,26], decidual
CD3
-/CD56
+ NK cells represent the main leukocyte
population in the decidual tissue (mean 58% ± 7.8).
Decidual leukocytes area l s oc o m p o s e do fC D 1 4
+ anti-
gen presenting cells (mean 19% ± 4.7) and CD3
+ T lym-
phocytes (mean 8% ± 5), including CD4
+ and CD8
+ T
lymphocytes (n = 21). Altogether, these results con-
firmed that the studied tissue was the decidua basalis, a
maternal tissue in direct contact with the placenta. Flow
cytometry analyzes show that both leukocytes (CD45
+)
and non-leukocytes (CD45
-) cells were present in decid-
ual mononuclear cells and that dNK cells are the main
leukocyte population.
Decidual culture supernatants contain soluble factors that
regulate HIV-1 infection
To identify soluble factors secreted by decidual cells, we
applied Luminex technology and ELISA methods to cul-
ture supernatants of decidua basalis mononuclear cells.
Cytokines were quantified after 24 hours of culture with-
out stimulation. Figure 3 shows the cytokines detected
according to their abundance: low (Figure 3A), medium
(Figure 3B), and high (Figure 3C). Cytokines detected at
low levels included IL-10 (mean 277 pg/ml ± 72), IL-12
(456 pg/ml ± 46), IL-15 (118 pg/ml ± 14), TNF-a
(372 pg/ml ± 107), IFN-a (71 pg/ml ± 6), IFN-g (86 pg/
ml ± 8) and CXCL-12 (148 pg/ml ± 36). Chemokines
detected at moderate or high levels included CCL-3
(11460 pg/ml ± 2367), CCL-4 (7272 pg/ml ± 1760), CCL-
5 (1492 pg/ml ± 300), CXCL-10 (11300 pg/ml ± 2260)
and CCL-2 (106 ng/ml ± 1.7). The pro-inflammatory
cytokines IL-6 (33 ng/ml ± 7.6) and IL-8 (3.10
3 ng/ml ±
953) were also abundant. The proinflammatory cytokine
IL-2 was undetectable (data not show), in keeping with
its known absence from the healthy maternofetal inter-
face [27].
The detected soluble factors were also present in similar
proportions, but at lower levels in decidua basalis and
decidua parietalis histoculture supernatants (data not
shown). IL-6 and IL-8 were significantly more abundant in
decidua basalis supernantants than in decidua parietalis
supernatants (p = 0.0012 and p = 0.01 respectively).
These results showed that decidual cells secreted solu-
ble factors known to regulate HIV-1 infection, including
b-chemokines known to inhibit R5 viral entry.
b-chemokine secretion increases during HIV-1 infection of
decidual cells
Decidua basalis culture supernatants were analyzed with
Luminex technology 14 days after infection, at a time of
sustained HIV-1 replication. As the culture medium was
renewed every 3 days, reported cytokine levels are those
having accumulated between day 11 and day 14. CCL-3
and CCL-4 were significantly more abundant (p = 0.026
and p = 0.027) in the supernatants of R5 HIV-1-infected
cells than of non-infected cells. CCL-5 was not signifi-
cantly more abundant in R5 HIV-1-infected cell superna-
tants 14 days after infection (p = 0.06)(Figure 4A).
In contrast to R5 HIV-1-infected cells, cytokine secre-
tion was not significantly modulated by X4 HIV-1 infec-
tion (Figure 4A and 4B). Production of IL-12, IL-6,
CCL-2, CXCL-10 and CXCL-12, that were also detected
at day 14, was not significantly affected by either R5 or
X4 HIV-1 infection (data not show).
Thus, CCL-3 and CCL-4 release by cultured decidua
basalis mononuclear cells was enhanced by R5 HIV-1
infection.
Decidual CD14
+ cells are the main sources of CCL-3 and
CCL-4
Luminex analysis showed that CCL-3 and CCL-4 release
was increased by R5 HIV-1 infection. To identify the
source of these chemokines, freshly isolated, HIV-1-unin-
fected decidua basalis mononuclear cells were analyzed by
flow cytometry after intracellular staining. CCL-3 and
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(CD45
-), natural killer cells (CD56
+ dNK), and antigen-
presenting cells (CD14
+ dAPC) (Figure 5A). The mean
fluorescence indexes (MFI) of CCL-3 and CCL-4 in cells
from decidua from 4 different women were higher in
dAPC than in non leukocytic and dNK cells (Figure 5B).
CD4
+ T cells and CD8
+ T cells both had very low MFIs
for CCL-3 and CCL-4.
Figure 1 Characterization of decidual mononuclear cells by immunochemistry. Frozen decidua basalis sections were stained with Isotype
matched Ig control (A), anti-CD34 (B), anti-Cytokeratin 7 (C), anti-CD14 (D), anti-CD56 (E) and anti-CD3 (F). Staining were visualized with
diaminobenzidine (brown cells in B, D, E and F) or Vector red (red cells in C) chromogen and tissue sections were counterstained with
haematoxylin. Images were taken at ×100 (A, B, C and E) or ×200 (D and F) magnification.
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CCL-4 were quantified by Luminex analysis in 3-day
culture supernatants of purified dAPC and dNK cells.
Large amounts of both CCL-3 and CCL-4 were detected
in dAPC supernatants (23 454 pg/ml ± 12 214 and 10
496 pg/ml ± 4 898, respectively) (Figure 5C). CCL-3 and
CCL-4 were also found in dNK cell supernatants, but at
lower levels (717 pg/ml ± 314; and 1 445 pg/ml ± 285,
respectively). Small amounts of CCL-5 were found in
both dAPC and dNK supernatants (452 pg/ml ± 325
and 291 pg/ml ± 50. respectively).
These results showed that dAPC were the main
sources of CCL-3 and CCL-4 in the decidua.
Decidual soluble factors can inhibit HIV-1 infection
To examine the role of the cytokine environment in the
inhibition of viral replication, decidua basalis mononuc-
lear cells were cultured for 24 hours before infection
with R5 HIV-1 or X4 HIV-1. The cells were then
infected, following a washing step or without a washing
step (i.e. in the presence or absence of their respective
24-hour supernatants). R5 HIV-1 infection of decidual
mononuclear cells was inhibited, as shown by the p24
antigen assay 7 days post-infection, in experiments with
6 out of 9 donors (range 0 to 80%, mean 28.64% ± 11.6;
p = 0.039) (Figure 6). Inhibitory activity was lower 10
days post-infection (mean 18.69% ± 9.6; p = 0.088).
Figure 2 Analyze of decidual mononuclear cells by flow
cytometry. Cells were gated on the leukocyte population (CD45
+).
Immune cells were identified by expression of surface markers such
as CD56 (dNK cells), CD14 (dAPC) and CD3 (dT cells). This
experiment is representative of n = 21 decidual samples.
Figure 3 Cytokine production by decidual mononuclear cells
after 24 hours of culture. Cytokines and chemokines were
quantified in 24-hour decidual cell supernatants without any
stimulation. Results are expressed in pg/ml, as measured with
Luminex technology. Cytokines were classified in 3 groups
according to their abundance. Bars represent the mean value of 13
different donors and the error bars indicate the SEM.
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Page 4 of 12Figure 4 Modulation of b-chemokine secretion by HIV-1 infection of decidual mononuclear cells. Decidual mononuclear cells were
infected with R5 and X4 HIV-1 (10
-3 MOI). (A) b-chemokine secretion was measured 14 days later, after 3 days of culture (day 11 to day 14):
uninfected control conditions (black dots), R5 HIV-1 (red dots) and X4 HIV-1 (blue dots). Results are expressed in pg/ml, as measured with
Luminex technology. Bars indicate the median values and each donor is represented by a different symbol. Significant changes are indicated. (B)
Results are the fold increase in secretion in HIV-1-infected cell culture supernatants compared to uninfected controls. Bars represent the mean of
the fold induction and error bars the SEM. At least 6 different donors were used for each experimental condition. Significant changes are
indicated by a star (p < 0.05). A one-sample t test was used.
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Page 5 of 12Figure 5 Identification of b-chemokine-producing cells among decidual mononuclear cells. (A) Decidual mononuclear cells were cultured
for 16 h with Brefeldin A then analyzed by flow cytometry, with gating on the main populations of decidual cells defined by their surface
markers. Intracellular staining of CCL-3 and CCL-4 (blue) was analyzed in each cell population and compared to IgG staining (red). Staining for
one representative donor is shown. (B) The mean fluorescence indexes (MFI) of b-chemokine staining were obtained for each cell population
after subtracting the IgG MFI. All analyses used at least 4 different donors. Bars represent the mean MFI and error bars the SEM. (C) b-
chemokines were measured in supernatants of purified dAPC and dNK cells after 3 days of culture, using 10 different donors for dAPC and 7
different donors for dNK. Bars represent the mean and error bars the SEM.
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experiments with 6 out of 9 donors, 10 days post-infec-
tion (mean 11.25% ± 11.9; p = 0.375)(Figure 6); how-
ever, in contrast to the effect on R5 HIV-1 infection, the
mean percentage of inhibition was not statistically
significant.
To determine whether decidual soluble factors inhib-
ited HIV-1 entry, the HeLa P4P cell line, which
expresses the CD4 HIV receptor and also the co-recep-
tors CCR5 and CXCR4, were infected by HIV-1 pseudo-
types in the presence or absence of 24 h decidual
conditioned medium (dCM). Efficiency of infection was
measured in terms of luciferase activity (representative
experiment in Figure 7A). dCM from 7 out of 8 donors
significantly reduced R5 HIV-1BaL pseudotype infection
(mean 32.9% ± 7, range 0-58.4%; p = 0.002), while HIV-
1VSV-G pseudotype infection was unaffected (mean
5.25% ± 10.7, p = 0.640) (Figure 7B). dCM from 5 out
of 7 donors reduced X4 HIV-1HxB2 pseudotype infec-
tion, but not significantly (mean 15.2% ± 13.1, range 0-
68%; p = 0.289).
Altogether, these results indicated that decidual cul-
ture supernatants participated in the inhibition of HIV-1
entry.
Discussion
This study suggests that soluble factors secreted by
decidual cells can inhibit HIV-1 infection. We first show
that decidual mononuclear cells produce soluble factors
known to modulate HIV-1 infection. Decidual cells were
cultured without exogenous stimulation, contrary to
some other studies [28,29]. The types and levels of the
cytokines detected in decidual mononuclear cell super-
natants were similar to those found in decidual histocul-
ture supernatants (data not show), suggesting that the
Figure 6 Inhibition of HIV-1 infection by decidual soluble
factors. Decidual mononuclear cells were cultured for 24 hours
without stimulation, then infected with R5 or X4 HIV-1 isolates (10
-4
MOI), following with or without a washing step. Viral replication was
measured by p24 viral antigen assay in culture supernatants 7 and
10 days post-infection. Results represent the percentage inhibition
of HIV-1 infection induced by decidual soluble factors compared
with experiments including a washing step. Mean viral p24 levels in
culture supernatants were 367 pg/ml at day 7 and 6839 pg/ml at
day 10 for R5 HIV-1; and respectively 42 at day 7 and 613 pg/ml at
day 10 for X4 HIV-1. Experiments used 9 different donors, each
represented by a different symbol, and lines indicate the mean
inhibition. Mean inhibition of R5 HIV-1 infection was statistically
significant at day 7 (mean 28.64% p = 0.039) but not at day 10
(mean 18.69% p = 0.088). Inhibition of X4 HIV-1 infection observed
at day 10 was not statistically significant (mean 11.25% p = 0.375).
Figure 7 Decidual soluble factors inhibit the HIV-1 entry step.
HeLa P4P cells were pretreated for 1 hour with fresh medium or 24
h decidual conditioned medium (dCM), and then infected with R5
HIV-1, X4 HIV-1 or VSV-G pseudotypes (6 ng of p24). (A) Luciferase
activity was measured 72 h post-infection. A representative
experiment is shown. (B) Experiments were performed individually
with dCM from at least 7 different donors. Bars indicate the mean
inhibition of pseudotype infection; and error bars the SEM.
Significant inhibition is represented by a star (p < 0.05). A one-
sample t test was used.
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modify the secretion profile. Decidual soluble factors
include cytokines known to stimulate HIV-1 infection
by promoting inflammation and viral replication includ-
ing IL-12, TFN-a, IL-6 and IL-8 [6,30,31], but also anti-
inflammatory (IL-10) and antiviral cytokines (IFN-a,
IFN-g, CXCL-12, CCL-3, CCL-4 and CCL-5) that inhibit
HIV-1 infection [3,4,32,33]. Interestingly, it has been
reported that the placenta secretes similar profiles of
pro- and anti-inflammatory cytokines to those observed
here with the decidua [34,35]. At the maternofetal inter-
face, this pro- and anti-inflammatory balance stimulates
leukocyte recruitment and angiogenesis, and regulates
placental trophoblast invasion during pregnancy. More-
over, this balance is described in other mucosae such as
the gut mucosa, where it is known to regulate micro-
flora tolerance and to prevent pathogen invasion [36].
We have previously shown that decidual mononuclear
cells are permissive for HIV-1 infection in vitro [24]. Here,
we found that secretion of the b-chemokines CCL-3 and
CCL-4 was significantly upregulated during R5 HIV-1
infection of decidual mononuclear cells, but not during X4
HIV-1 infection. Some viral proteins, such as Nef, are
known to induce b-chemokine production [37]. R5 HIV-1
replicates more efficiently than X4 HIV-1 in decidual cells
[24]. The observed increase in b-chemokine secretion dur-
ing R5 HIV-1 infection could therefore be due to HIV-1
replication. Similar b-chemokine upregulation during
HIV-1 infection has also been described in other tissue
types, such as lymph nodes and gut-associated lymphoid
tissue [38]. This increased b-chemokine secretion was sus-
pected of promoting viral dissemination during the pri-
mary infection, through recruitment of immune cells,
including HIV-1 target cells [38]. On the other hand, ele-
vated b-chemokine production could also participate in
the control of HIV-1 spread, as these soluble factors have
been reported to inhibit cell-to-cell HIV-1 infection [23].
Moreover, CCL-3, CCL-4 and CCL-5 are known to inhibit
R5 HIV-1 entry by competitively binding CCR5 [3]. b-
chemokines might limit the number of infected cells
within the decidua and such limit the risk of transmission
to the fetus due to the contact of decidual infected cell
and placental trophoblast cells. We found that the main
source of CCL-3 and CCL-4 in the decidua was CD14
+
cells. We detected no CCL-5 production by purified dNK
cells or decidual CD14
+ cells when using flow cytometry,
while small amounts of CCL-5 were detected in both cul-
tures when we used Luminex technology. We have pre-
viously shown that dAPC CD14
+ cells are the main
decidual cell target of R5 HIV-1 [24]. Thus, secretion of
HIV-1-inhibiting factors by these cells could constitute a
mechanism of autocrine protection, as previously
described with peripheral CD4
+ T lymphocytes [39]. The
latter authors found that CD4
+ T lymphocytes, which
produce the chemokine CCL-4, were 10 times less infected
in vivo than cells that did not produce CCL-4.
Decidual soluble factors inhibited R5 HIV-1 infection;
and, to a lesser extent, X4 HIV-1 infection, variably from
one donor to another. In addition, R5 HIV-1 inhibition
was higher at day 7 than at day 10, pointing to an effect
on the viral entry step. Similarly, X4 HIV-1 inhibition
was weaker at day 14 than at day 10, while no significant
replication was noted at day 7. We have previously
shown that X4 HIV-1 infects decidual mononuclear cells
less efficiently than R5 HIV-1 [24]. To confirm that
decidual soluble factors inhibit the viral entry step, we
used HIV-1 pseudotypes. Decidual soluble factors inhib-
ited the entry of HIV-1 pseudotypes bearing the HIV-1
(R5 or X4) envelope but not the entry of the VSV-G-
bearing HIV-1 pseudotype, which is independent of
receptor usage. Inhibitory activity did not correlate
directly with the level of CCL-3, CCL-4 or CCL-5, or
with the total amount of b-chemokines (data not shown).
However, we assayed the chemokines in cell superna-
tants, and it is conceivable that decidual cells consume a
proportion of the b-chemokines they secrete. Further-
more, other decidual soluble factors might also be
involved in inhibiting HIV-1 infection, possibly in
synergy with b-chemokines. Antimicrobial peptides can
inhibit HIV-1 entry in target cells [40-43], and have been
detected in human decidua [44] and the female reproduc-
tive tract [45,46]. High levels of antimicrobial peptides
have been detected in vaginal secretions from HIV-1-
exposed but uninfected individuals [47] and have been
linked to a low rate of mother-to-child transmission [48].
Inhibition of HIV-1 infection by decidual soluble factors
including b-chemokines, appears to constitute a protective
mechanism. In view of the large inter-individual differ-
ences in the degree of viral inhibition observed here, other
mechanisms might contribute to the control of HIV-1
transmission at the maternofetal interface. We found that
dNK cells also produced CCL-3, CCL-4 and CCL-5, sug-
gesting that they could have a role in the control of HIV-1
transmission. A recent study has shown that NK cells
from non-pregnant uterine mucosa can inhibit X4 HIV-1
infection by secreting high levels of CXCL-12 [49]. NK
cells are the main decidual immune cell population [20]
and cross-talk with dAPC appears to be crucial for main-
tenance of pregnancy [50-52]. Interactions between dNK
cells and dAPC might stimulate the production of anti-
HIV-1 factors and thus enhance autocrine protection of
target cells.
Conclusion
We report that decidual mononuclear cells naturally
produce large amounts of chemokines, and that R5
HIV-1 infection significantly enhances production of the
b-chemokines CCL-3 and CCL-4. The main source of
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+ antigen-present-
ing cells, which are also the main decidual target cell for
R5 HIV-1. Furthermore, we provide evidence that decid-
ual soluble factors, including b-chemokines, participate
in inhibiting HIV-1 entry in the decidua. These findings
a l s os u g g e s tt h a tt h ef i r s tt r i m e s t e rm a t e r n o f e t a li n t e r -
face is a relevant model for studying determinants of
natural protection against mucosal HIV-1 infection.
Materials and methods
Human decidual tissue
Decidual tissue samples were obtained from healthy
women undergoing voluntary termination of pregnancy
during the first trimester (6-10 weeks) at Antoine Béclère
Hospital, Clamart, France and Tenon Hospital, Paris,
France. All the women gave their written informed con-
sent to the use of their tissues. The study was approved by
the ethics committee of Hôtel Dieu, Paris, France, the
Assistance Publique des Hôpitaux de Paris (n° VAL/2006/
06-41/01) and the Biomedical Research Committee of the
Institut Pasteur, Paris, France (n° RBM/2005.024).
Histocultures of decidua parietalis and decidua basalis
were performed as previously described by Marlin et al
[24].
For cell isolation, freshly isolated decidual tissue was
minced into small fragments and digested for 1 hour at
37°C under agitation in RPMI 1640 culture medium
(Gibco) with 1 mg/ml collagenase IV (Sigma, St Quentin
Fallavier, France) and 50 U/ml recombinant DNase I
(Roche, Meylan, France). The cell suspension was succes-
sively filtered through 100 μm, 70 μma n d4 0μmp o r e -
size sterile nylon cell strainers (BD Biosciences, Le pont de
Claix, France). The mononuclear cell population was iso-
lated with Lymphocyte Separation Medium (PAA) and
cultured in the rich culture media Ham F12: DMEM Glu-
tamax (v:v) (Gibco) supplemented with 15% foetal calf
serum (PAA, Les Mureaux, France), penicillin (0.1 U/l)
and streptomycin (1 × 10
-8 g/l) (Gibco). CD14
+ and NK
cells were purified with anti-CD14 and anti-CD56 mag-
netic beads, respectively, as recommended by the manu-
facturer (Miltenyi, Paris, France).
HIV-1 primary isolates and pseudotypes
Decidual histocultures and decidual mononuclear cells
were infected with two HIV-1 primary isolates, HIV-
1BaL and HIV-1LAI (with R5 or X4 tropism respectively).
The isolates were amplified on PHA-stimulated PBMC
f r o mt w ob l o o dd o n o r sf o r1 0d a y s .P B M Cc u l t u r e s
were maintained in RPMI 1640 Glutamax (Gibco) sup-
plemented with 10% fetal calf serum, penicillin, strepto-
mycin and 100 U/ml recombinant interleukin-2
(Chiron-Nederlands). Virions were concentrated by cen-
trifugation on Vivaspin 100 000 Kda (Sartorius, Palai-
seau, France) at 1400 g for 40 minutes.
Luciferase-expressing viral pseudotypes were based on
the NL4-3 HIV-1 and VSV-G (amphotropic), BaL (R5) or
HxB2 (X4) env plasmids [53-55]. The viral pseudotypes
were generated by transfecting HEK-293T cells with the
corresponding cDNA plasmid (pNL4-3ΔEnvLuc+ plus the
appropriate env cDNA) using the transfection reagent
SuperFect transfection reagent (Qiagen) as directed by the
manufacturer. The pNL4-3ΔEnvLuc+ lacks the nef gene
and the resulting pseudotype is non replicative. Superna-
tants were collected 72 hours after transfection, assayed
for the viral pseudotypes by means of p24 antigen ELISA
(Zeptometrix) and titrated on HeLa P4P cells. The effi-
ciency of infection by the viral pseudotypes was deter-
mined by measuring luciferase expression with Luciferase
Reagent (Promega) and a Glomax luminometer.
Immunohistochemistry
Decidual sections were obtained by embedding freshly iso-
lated decidual tissue in Tissue-Tek (Sakura, Gentaur,
P a r i s ,F r a n c e )a n ds n a p - f r o z e ni na ni s o p e n t a n e / l i q u i d
nitrogen bath. Frozen Tissue-Tek blocks were cut with a
cryostat and frozen sections (5 μm thick) were fixed in
acetone and rehydrated in TBS (Dako, Trappes, France).
Tissue sections were stained for CD14 (RMO52, Beckman
Coulter), CD3 (F7.2.38, Dako), CD34 (QbEnd10, Beckman
Coulter), CD56 (N901, Beckman Coulter) or Cytokeratin 7
(OV-TL 12/30, Dako). Endogenous peroxidase and alka-
line phophatase (AP) were blocked for 10 minutes by addi-
tion of hydrogen peroxide and levamisol (Dako). Surface
markers were visualized using the Envision+ dual link sys-
tem (Dako), or using biotin-streptavidin-alkaline phospha-
tase complex and Vector Red (Abcys, Paris, France), as an
AP substrate. Tissue sections were counterstained with
haematoxylin (Labonord, templars, France), mounted in
permanent medium and analysed with a Nikon Eclipse 80i
microscope.
Cytokine assays
The main cytokines involved in the regulation of HIV-1
infection, namely IL-2, IL-10, IL-12, IL-15, TNF-a,I F N - a,
IFN-g,C C L - 3( M I P 1 - a), CCL-4 (MIP1-b), CCL-5
(RANTES), IL-6, IL-8, CXCL-10 (IP10) and CCL-2
(MCP1) were measured by Luminex assay (Human Cyto-
kine 25-plex antibody bead kit, Invitrogen Corporation,
Carlsbad, California). CXCL-12 (SDF1) was measured with
the Human SDF1 Quantikine Immunoassay (R & D Sys-
tem, Minneapolis) in the manufacturer’s recommended
conditions. The cytokines were measured in supernatants
of unstimulated decidual mononuclear cells collected after
24 hours of culture, or after 72 hours in the case of puri-
fied dAPC CD14
+ and dNK cells, when cytokine concen-
trations were maximal in the culture supernatants. To
compare cytokine production by infected and non-infected
decidual mononuclear cells, 3-days of cultured
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Page 9 of 12supernatants (day 11 to day 14) were assayed 14 days after
infection with or without HIV-1BaL or HIV-1LAI.
Identification of cytokine-producing cells
Decidual mononuclear cells were tested for chemokine
production by flow cytometry. After isolation, cells were
cultured for 16 hours with Brefeldin A (Sigma-Aldrich)
at 5 μg/ml, then labelled with anti-CD45-Amcyan, anti-
CD14-Pacific Blue, anti-CD4-PE-Cy7, anti-CD56-Alexa
700 (Becton Dickinson), anti-CD3-PE-TexasRed and
anti-CD8-APC (Beckman Coulter) before fixation and
permeabilisation with the Intraprep reagent (Beckman
Coulter). The cells were then labelled with anti-CCL-3-
FITC, anti-CCL-4-FITC, anti-CCL-5-FITC (R & D Sys-
tem, Minneapolis) or IgG-FITC (control). Flow cytometry
was performed with an LSRII device (Becton Dickinson)
and FlowJo 9.0.1 software.
HIV-1 infection
Decidual mononuclear cells were incubated for 1 hour
with HIV-1 isolates or uninfected PBMC supernatant, at
10
-3 MOI, then washed 3 times and cultured at 10
6
cells/ml. Viral production was measured every 3 or 4
days by detection of p24 antigen in cell culture superna-
tants by ELISA (Zeptometrix).
Inhibition of viral production
To examine the influence of the cytokine environment
on the inhibition of viral replication, decidual mononuc-
lear cells were cultured for 24 hours before infection with
HIV-1BaL or HIV-1LAI. After 24 hours, the cells were
infected with 10
-4 MOI for 1 hour at 37°C following or
not a washing step. After 3 washes post-infection, the
cultured cells were resuspended in culture medium and
HIV-1 p24 antigen was titrated by ELISA in the culture
supernatants at day 7 and day 10.
HIV-1 entry inhibition assays
HeLa P4P cells (CD4
+ CCR5
+ CXCR4
+) [56] were seeded
at 10
4 cells/well and cultured for 24 hours in 96-well
plates. Entry inhibition assays were performed by incubat-
ing the cells for 1 hour with 100 μl of decidual conditioned
medium collected after 24 h of decidual mononuclear cell
culture, or with fresh culture medium (Mock medium),
followed by treatment with 6 ng of p24 equivalent of each
HIV pseudotype for 1 hour. The cells were then washed in
1X phosphate buffered saline (PBS) and cultured for
72 hours at 37°C. HeLa P4P cells were washed in 1X PBS
and lysed with 100 μl of Cell Lysis Buffer (Promega). The
cell lysates (10 μl) were used to determine luciferase activ-
ity as described above. Results are expressed as Relative
Light Units (RLU)/100 μl of lysate. Each experimental con-
dition was performed in triplicate.
Statistical analysis
Each condition was tested in at least four independent
experiments. The one-sample t test was used. The
hypothetical value was 1 for the fold-change graph and
0 for the percentage inhibition graph. Significance was
assumed at p < 0.05. Prism 4 software (Graph Pad) was
used for all analyses.
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